

Effective: December 1, 2023

Guideline Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Non-Formulary <input type="checkbox"/> Step-Therapy <input type="checkbox"/> Administrative
Applies to: Public Plans Products <input checked="" type="checkbox"/> Tufts Health RITogether – A Rhode Island Medicaid Plan; Fax 617-673-0988	

Note: While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

Overview

Food and Drug Administration - Approved Indications:

Amvuttra (vutrisiran) is a transthyretin-directed small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Onpattro (patisiran) contains a transthyretin-directed small interfering RNA and is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR-FAP) in adults.

Clinical Guideline Coverage Criteria

The plan may authorize coverage of Amvuttra or Onpattro for Members when all the following criteria are met:

Initial Authorization Criteria

1. Documented diagnosis of hereditary transthyretin-mediated amyloidosis with polyneuropathy
AND
2. Documentation in the patient's medical record of transthyretin (TTR) mutation
AND
3. Prescribed by or in consultation with a neurologist or physician specializing in the treatment of amyloidosis
AND
4. Documentation of baseline Polyneuropathy Disability (PND) score of IIIb or lower
AND
5. The patient is at least 18 years of age
AND
6. Documentation the patient has not had a prior liver transplant
AND
7. Documentation the requested medication will not be used concomitantly with another medication indicated for the management of cardiomyopathy or neuropathy of transthyretin-mediated amyloidosis (e.g., Tegsedi, Vyndamax)

Reauthorization Criteria

1. Documented diagnosis of hereditary transthyretin-mediated amyloidosis with polyneuropathy
AND
2. Documentation in the patient's medical record of transthyretin (TTR) mutation
AND
3. The patient is at least 18 years of age
AND
4. Prescribed by or in consultation with a neurologist or a provider specializing in the treatment of amyloidosis
AND
5. Documentation the requested medication will not be used concomitantly with another medication indicated for the management of cardiomyopathy or neuropathy of transthyretin-mediated amyloidosis (e.g., Tegsedi, Vyndamax)
AND
6. Documentation of both of the following:
 - a. Polyneuropathy disability (PND) score has remained a score of IIIb or lower
 - b. Positive clinical response as evidenced by improved or stable motor function, neurologic impairment, and quality of life

Limitations

- Initial coverage of Amyloidosis Therapies will be authorized for 12 months. Reauthorization of Amyloidosis Therapies will be provided in 12-month intervals.
- Members new to the plan stable on treatment with Amyloidosis Therapies must meet Initial Authorization criteria if on treatment for less than a year and must meet Reauthorization criteria if on treatment for more than a year.

Codes

The following code(s) require prior authorization:

Table 1: HCPCS Codes

HCPCS Codes	Description
J0222	Injection, patisiran, 0.1 mg
J0225	Injection, vutrisiran, 1 mg

References

1. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379(1):11-21.
2. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin -related hereditary amyloidosis for clinicians. *Orphanet Journal of Rare Diseases*. 2013;8(31):1-18.
3. Amvuttra (vutrisiran) [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; June 2022.
4. Benson MD, Waddington-Cruz M, Berk J, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379(1):22-31.
5. Brannagan T, Wang AK, Coelho T, et al. Open label extension of the phase 3 study NEURO-TTR to assess the long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis. *Neurology*. 2018;90(15 Suppl). Abstract P1.324.
6. Lasser KE, Mickle K, Chapman R, et al. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value. Evidence report. 2018 August 29. Available from Internet. Accessed 2018 September 12.
7. Onpattro (patisiran) [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; May 2021.
8. Suhr OB, Gonzalez-Duarte A, O'Riordan W, et al. Long-term use of patisiran, an investigational RNAi therapeutic, in patients with hereditary transthyretin-mediated amyloidosis: baseline demographics and interim data from global open label extension study. Presented at 2018 International Symposium on Amyloidosis. Kumamoto, Japan; 2018 March.

Approval And Revision History

September 13, 2022: Reviewed by Pharmacy and Therapeutics Committee (P&T)

Subsequent endorsement date(s) and changes made:

- September 21, 2022: Reviewed by the Medical Policy Approval Committee (MPAC)
- December 22, 2022: Administrative update: Amvuttra code J0225 added, effective January 1, 2023
- September 12, 2023: Minor wording changes to make coverage criteria more concise and clearer. Removed the following from Initial Authorization Criteria: “Member exhibits clinical manifestations of ATTR-FAP (transthyretin-type familial amyloid polyneuropathy), e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy.” Updated requirements for demonstration of a clinical benefit in the Reauthorization Criteria. Added “Documentation the requested medication will not be used concomitantly with another medication indicated for the management of cardiomyopathy or neuropathy of transthyretin-mediated amyloidosis (e.g., Tegsedi, Vyndamax)” and removed the Limitation “Combination hereditary amyloidosis product therapy will not be authorized.” Removed the Limitation “Treatment of sensorimotor or autonomic neuropathy not related to hereditary transthyretin- mediated amyloidosis will not be approved.” (effective 12/1/2023).

Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member’s benefit document, and in coordination with the Member’s physician(s) on a case-by-case basis considering the individual Member’s health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member’s benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.